Ney Carter Borges: The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:
“The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
The vascular endothelium is a highly specialized, metabolically active organ that plays a pivotal role in cardiovascular homeostasis. It regulates vascular tone, platelet activity, leukocyte adhesion, oxidative balance, and thrombosis primarily through the synthesis of vasoactive mediators, notably nitric oxide (NO). In healthy individuals, endothelial cells maintain high NO bioavailability, which promotes vasodilation, inhibits smooth muscle proliferation, suppresses inflammation, and prevents platelet aggregation.
Epidemiological and mechanistic studies consistently demonstrate that endothelial dysfunction precedes overt atherosclerosis by decades. Flow-mediated dilation (FMD), a validated marker of endothelial function, declines progressively with age—approximately 0.5–1.0% per decade in low-risk populations—and is markedly impaired in individuals with traditional cardiovascular risk factors. Large cohort studies show that a 1% reduction in FMD is associated with an 8–13% increase in future cardiovascular events.
Reduced NO bioavailability is a hallmark of endothelial dysfunction and is strongly linked to atherosclerotic progression. Experimental and clinical data indicate that NO production may decline by 40–60% in middle-aged adults with metabolic syndrome or diabetes, accelerating lipid oxidation, vascular inflammation, and plaque formation. In advanced stages, severe NO depletion (<20% of physiological levels) is associated with arterial stiffening, plaque instability, and a significantly increased risk of thrombotic events.
Clinically, endothelial dysfunction independently predicts myocardial infarction, stroke, and cardiovascular mortality, even after adjustment for conventional risk factors. Meta-analyses involving over 20,000 patients demonstrate that impaired endothelial function confers a 1.7–2.3-fold higher risk of major adverse cardiovascular events. These findings underscore that endothelial health is not merely a marker but a central driver of cardiovascular disease complexity, progression, and clinical outcomes—making it a critical therapeutic target in modern preventive cardiology.”

More posts featuring Ney Carter Borges.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation